Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain

Recruiting in Palo Alto (17 mi)

+47 other locations

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Eli Lilly and Company

Prior Safety Data

Trial Summary

What is the purpose of this trial?This trial is testing a new medication called LY3526318 to see if it can help people with diabetic nerve pain. The study focuses on those who have chronic pain due to nerve damage from diabetes. Researchers want to find out if this drug can safely reduce their pain by blocking pain signals.

Eligibility Criteria

Participant Groups

2Treatment groups

Experimental Treatment

Placebo Group

Group I: LY3526318Experimental Treatment1 Intervention

Participants received 250 milligram (mg) of LY3526318 orally, once daily for the first 4 weeks and were switched to placebo once daily for the next 4 weeks of the treatment period.

Group II: PlaceboPlacebo Group1 Intervention

Participants received placebo orally, once daily, for 8-weeks treatment period.